SG-55 | AKR1C3 inhibitor

CAS:
 N/A
Catalog Number:
 10-4386
SG-55 chemical structure

Available Options

Size:PriceQuantity 
5 mg$70.00
25 mg$250.00
Request Quote / Bulk / Custom Size
Product Inquiry

SG-55 is a noncompetitive AKR1C3 inhibitor (IC50 = 5 nM) with high selectivity over other isoforms. It synergized with Osimertinib in EGFR mutant cancer cells to suppress cell proliferation, clonogenicity, and survival.  SG-55 resensitized PC-9/OR triple mutant NSCLC cells to Osimertinib treatment.  Active in vivo.

References/Citations:

  1. Guo et al. (2026), Discovery of Highly Selective AKR1C3 Inhibitors to Overcome EGFR C797S-Mediated Osimertinib Resistance in Non-Small Cell Lung Cancer; J. Med. Chem. 69 6399
AKR1C3 inhibitor, SG-55, SG-55 supplier, SG55
CAS:
N/A
Catalog Number:
10-4386
Activity:
AKR1C3 inhibitor
Chemical Names:
2-{[4-(Cyclopropylcarbonyl)-1H-pyrrol-2-yl]-carbonyl}-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile
Molecular Weight:
319.36
Molecular Formula:

C19H17N3O2

Solubility:
Soluble in DMSO (40 mg/ml)
Physical Properties:
Off-white to beige solid
Purity:

>98% HPLC
NMR: (Conforms)

Storage Temperature:
-20°C
Stability:
Stable for up to 2 years when stored as supplied @ -20°C. Solutions in DMSO may be stored at -20°C for up to 3 months.
Shipping Code:
RT

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

SG-55 is a noncompetitive AKR1C3 inhibitor (IC50 = 5 nM) with high selectivity over other isoforms. It synergized with Osimertinib in EGFR mutant cancer cells to suppress cell proliferation, clonogenicity, and survival.  SG-55 resensitized PC-9/OR triple mutant NSCLC cells to Osimertinib treatment.  Active in vivo.

References/Citations:

  1. Guo et al. (2026), Discovery of Highly Selective AKR1C3 Inhibitors to Overcome EGFR C797S-Mediated Osimertinib Resistance in Non-Small Cell Lung Cancer; J. Med. Chem. 69 6399

STEM CELL

BOGO